">

Monday, May 26, 2008

 

Should Mesothelioma Victims Call A Mesothelioma Victims Center?

070517-G-1286H-755
Mesothelioma Victims Should Call Americas Watchdog's Mesothelioma Victims Center

If you are a victim of Mesothelioma or a family member friend of a victim Americas Watchdog is there for you. Americas Watchdog has created the Mesothelioma Victims Center as a free service to victims or family members of victims, of a rare form of cancer called Mesothelioma. Americas Watchdog has initiated this very complete free service because there was literally nothing close to this type of service in the United States and because this type of service is sorely needed by Mesothelioma victims and their families. The Mesothelioma Victims Center was created to assist victims & their families in every way possible

April 21, 2008 -- Americas Watchdog has created the most wonderful service for victims or family members of victims of Mesothelioma. Until a family member was diagnosed with Mesothelioma, Americas Watchdog had never heard of this disease or knew much about it. Mesothelioma is a rare and lethal form of cancer. Mesothelioma is caused by exposure to asbestos. The group never realized that there was no safety net for victims, to get help from the government. They did not know how difficult it might be to get veterans benefits or social security benefits. Americas Watchdog also discovered that it is critical for victims of this lethal disease to get proper legal representation. They have designed the Mesothelioma Victims Center to be the national advocacy center for the victims and family members of Mesothelioma.Their service is free. The web site is located at http://MesotheliomaVictimsCenter.com.

Their services include:
* Assisting the victims obtain Social Security permanent disability payments
* If the victim is a veteran and was exposed to asbestos during military duty, we will work with the victim and his/her family in obtaining veterans disability and health care benefits.
* We will assist the family in getting the best possible
health care options
* We will assist the victim in
getting legal representation.
* We will assist the victim and their family in getting counseling on a wide variety of topics that arise from this
disease.
A victim of Mesothelioma or their family can call the group any time at 866-714-6466.

Who Can Get Mesothelioma? Individuals exposed to asbestos. As Follows
* Individuals who served in the US Navy. Especially Navy personnel who served in or around naval ship engine rooms.
* Members of the US Army, Air Force, Marines, or Coast Guard.
* Naval ship yard workers
* Ship yard workers
* Automotive repair specialists
* Construction workers
* Plumbers
* Demolition contractors

Because no other group is providing this full range of services and because victims and their families need assistance in these areas, Americas Watchdog is doing this at no charge because its the right thing to do. Americas Watchdog's Mesothelioma Victims Center web site is located at Http://MesotheliomaVictimsCenter.Com . Any one wishing more information can call the Mesothelioma Victims Center anytime at 866-714-6466.

Americas Watchdog and its Mesothelioma Victims Center are all about taking care of precious souls in need and corporate responsibility.

Press Contact: THOMAS MARTIN
Company Name: Americas Watchdog
Phone: 866-714-6466
Website:
Http://MesotheliomaVictimsCenter.Com

Enhanced by Zemanta

Labels: , , , , , , ,


Wednesday, May 21, 2008

 

Mesothelioma Blog Reports on Man Fired for Reporting Asbestos Cleanup

LegalView Mesothelioma Blog Reports on Whistleblower Who Was Allegedly Fired for Reporting Improper Asbestos Cleanup to Authorities

LegalView recently updated its mesothelioma blog to include reports of a whistleblower being fired after he reported improper asbestos cleanup. The worker who refused to sign off on the demolition of the school was dismissed from his job duties permanently after he reported the improper procedure cleanup to officials.

Denver, CO  -  April 18, 2008 -- LegalView, the number one resource for everything legal on the Web, recently updated its mesothelioma blog with news of the firing of an alleged whistleblower who attempted to report improper asbestos cleanup of a local high school. The city worker was part of a crew that was to demolition an old schoolhouse. The worker allegedly told city managers that the schoolhouse was filled with asbestos and would be hazardous if improper asbestos removal procedures were not followed. However, after the worker refused to sign off on the demolition and spoke out, he was fired, according to reports.

Asbestos is a hazardous chemical that is often found in insulation of many older buildings including government buildings, offices, homes, apartments, universities and schools. It is derived of vermiculite, which was heavily mined early on in the 20th century throughout the world. Asbestos was revered for its qualities of being cost efficient and its ability to insulate sufficiently without catching on fire as easily as other insulations. However, it was discovered that breathing in asbestos fibers and dust caused a deadly form of lung cancer to develop. Additionally, areas that currently contain asbestos must follow strict procedures and methods from the Environmental Protection Agency (EPA) for removal, otherwise asbestos fibers will likely be released into the air and contaminate surrounding areas and individuals. Those who feel they have been previously exposed to asbestos fibers should contact a mesothelioma lawyer for immediate assistance on building a case.

Mesothelioma cancer can take years to develop and is incurable. It is often misdiagnosed, as symptoms of mesothelioma cancer are similar to many other illnesses. Individuals who have contracted mesothelioma should speak with an experienced medical attorney and receive a consultation on a potential mesothelioma lawsuit. To learn more about this recent mesothelioma blog posting as well as additional up-to-date news, reports and information on recent mesothelioma jury verdicts, visit http://mesothelioma.legalview.com/.

In addition to the extensive mesothelioma information portal, LegalView offers information on an assortment of other legal issues that may disrupt the lives of millions of Americans. Information on issues such as pharmaceutical investigations, including the latest Singulair recall, preventable conditions like Erb's Palsy, diseases, illnesses, accidents, chemical exposure, employment discrimination, etc.

LegalView even provides news on the most recent traumatic brain injury treatments, available through LegalView's Web site. Also on the brain injury site, readers can find information on what may be involved with filing a brain injury lawsuit.

On the Singulair practice area, readers will be able to access the latest news on the prescription drug, which had been under investigation by the U.S. Food and Drug Administration (FDA) after reports began to surface about Singulair side effects that can allegedly include moodiness, suicidal behaviors and thoughts.

Additionally, using the Erb's Palsy information portal will provide victims and their families insight into the cause of their condition as well as opportunities for developing an Erb's Palsy lawsuit for potential monetary compensation to help pay for costly medical bills commonly associated with this condition. Erb's Palsy can be a debilitating condition and is usually preventable. It is associated with birth-canal complications that have occurred when an infant's shoulders or head became lodged, causing damage to the nerve system controlling arm movement. While Erb's Palsy often can clear on its own through time, many individuals still require physical therapy and many will need surgery to fix their condition. Those who suffer from this disease are advised to use LegalView's site to easily be referred to a qualified Erb's Palsy lawyer.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at
www.LegalView.com.

Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website:
http://mesothelioma.legalview.com


Sunday, May 18, 2008

 

Center to Assist All Victims of Mesothelioma

Mesothelioma Victims Center to Assist All Victims of Mesothelioma

Americas Watchdog has created the Mesothelioma Victims Center as a free service to victims or family members of victims, of a rare form of cancer called Mesothelioma. Americas Watchdog has initiated this very complete free service because there was literally nothing close to this type of service in the United States and because this type of service is sorely needed by Mesothelioma victims and their families. The Mesothelioma Victims Center was created to assist victims & their families in every way possible.

April 16, 2008 -- Americas Watchdog has just opened its Mesothelioma Victims Center, as a way to assist and protect victims of a rare form of cancer called Mesothelioma. The service is free to Mesothelioma victims or their families.

Until a family member was diagnosed with Mesothelioma, Americas Watchdog had never heard of this disease or knew much about it. Mesothelioma is a rare and lethal form of cancer. Mesothelioma is caused by exposure to asbestos. The group never realized that there was no safety net for victims, to get help from the government. They did not know how difficult it might be to get veterans benefits or social security benefits. Americas Watchdog also discovered that it is critical for victims of this lethal disease to get proper legal representation. They have designed the Mesothelioma Victims Center to be the national advocacy center for the victims and family members of Mesothelioma.Their service is free.

Their services include:
* Assisting the victims obtain Social Security permanent disability payments
* If the victim is a veteran and was exposed to asbestos during military duty, we will work with the victim and his/her family in obtaining veterans disability and health care benefits.
* We will assist the family in getting the best possible health care options
* We will assist the victim in getting legal representation.
* We will assist the victim and their family in getting counseling on a wide variety of topics that arise from this disease. A victim of Mesothelioma or their family can call the group any time at 866-714-6466.

Who Can Get Mesothelioma?

* Individuals who served in the US Navy. Especially Navy personnel who served in or around naval ship engine rooms.
* Members of the US Army, Air Force, Marines, or Coast Guard.
* Naval shop yard workers
* Ship yard workers
* Automotive repair specialists
* Construction workers
* Plumbers
* Demolition contractors

Because no other group is providing this full range of services and because victims and their families need assistance in these areas, Americas Watchdog is doing this at no charge because its the right thing to do. Americas Watchdog's Mesothelioma Victims Center web site is located at Http://MesotheliomaVictimsCenter.Com . Any one wishing more information can call the Mesothelioma Victims Center anytime at 866-714-6466.

Americas Watchdog and its Mesothelioma Victims Center are all about taking care of precious souls in need and corporate responsibility.

Press Contact: THOMAS MARTIN
Company Name: Americas Watchdog
Phone: 866-714-6466
Website:
http://MesotheliomaVictimsCenter.Com


Tuesday, May 13, 2008

 

Oral Cancer Now Covered under Specialty Benefits Dental Plans

`Early Warning' for Oral Cancer Now Covered under UnitedHealthcare Specialty Benefits Dental Plans

Coverage Applies to New Screening Test Used by Dentists

GOLDEN VALLEY, Minn.-- May 13, 2008 --UnitedHealthcare Specialty Benefits now provides coverage under all of its insured dental plans for a new oral cancer screening test for potential abnormalities inside the mouth, including premalignant lesions and oral cancer.

The test, which uses light-contrast technology, can improve a dentist's ability to identify, evaluate and monitor lesions that are difficult to see using visual inspection under conventional lighting.

"Evidence shows that dentists can serve as a valuable 'early warning' system for patients who have signs of oral cancer," said Dr. Michael Weitzner, vice president of clinical product development for UnitedHealthcare Specialty Benefits dental unit.

More than 34,000 Americans will be diagnosed with oral or pharyngeal cancer this year. The death rate associated with this cancer is particularly high - not because it is hard to discover or diagnose, but due to the cancer being routinely discovered late in its development. Studies confirm that survival does correlate with stage, making early diagnosis and treatment optimal for this disease and may have a positive impact on an individual's medical costs (Journal of the American Dental Association, Vol. 132, Nov. 2001).

By covering this type of oral cancer screening, UnitedHealthcare Specialty Benefits dental unit is renewing its longstanding commitment to early detection of oral cancer. In addition to oral cancer screening, UnitedHealthcare Specialty Benefits dental plans have covered brush biopsies since 2005 when the American Dental Association first introduced a current dental terminology (CDT) code for the procedure. Screening is covered once a year for individuals, starting at age 30. UnitedHealthcare Specialty Benefits' focus on wellness continues to build programs and plan enhancements that promote individuals' ability to better manage their overall health as well as their future medical and dental costs.

About UnitedHealthcare Specialty Benefits

UnitedHealthcare Specialty Benefits offers a broad array of specialty benefits, including vision, dental, group and voluntary insurance, worksite individual insurance and non-insurance programs. UnitedHealthcare Specialty Benefits is a business unit of OptumHealth, the health and wellness unit of UnitedHealth Group, Inc. (NYSE:UNH). More information about OptumHealth can be found at www.optumhealth.com/.

Contacts

OptumHealth
Ann Fleischauer, Director, External Communications
763-797-2652


Friday, May 09, 2008

 

South African Ban on Mesothelioma-Causing Asbestos

LegalView Updates Mesothelioma Blog Readers with News of South African Ban on Mesothelioma-Causing Asbestos

LegalView, on its mesothelioma blog, recently reported an asbestos ban on the use, manufacture and processing of the cancer-causing contaminant. Asbestos was mined for decades in South Africa and since the 1960s mesothelioma cancer and related illnesses have been associated with inhalation of the deadly fibers.

Denver, CO  -  April 11, 2008 -- LegalView.com recently reported on its mesothelioma blog the ban of asbestos in South Africa. The Environmental Affairs and Tourism Minister there announced the ban with regards to the use, manufacture and processing of asbestos, which causes a deadly form of lung cancer known as mesothelioma. The South African ban marks the latest addition to a worldwide effort to ban the mineral. Currently, approximately 50 countries around the globe have prohibited the production of the contaminant. For years, asbestos was mined in the area and, according to news reports, accounted for 3 percent of the value of all of the area's minerals. To learn more about how to locate mesothelioma attorneys in your area, which may be able to provide consultation on the effects of asbestos exposure.

Asbestos, which is derived from vermiculite - the mineral mined throughout the world and the source of asbestos, was widely used in a variety of construction projects such as the main source of installation in millions of homes, apartments, schools, universities, and business and government buildings worldwide. Individuals who have been exposed to asbestos should not only speak with a medical professional immediately, but should consider finding a mesothelioma lawyer as well.

Often it isn't until years after initial exposure to asbestos that individuals begin to notice symptoms of the inhaled asbestos fibers; the end result is usually an incurable lung cancer. Victims of this cancer in need of a mesothelioma attorney should utilize LegalView's referral service to connect them with any of the many mesothelioma lawyers available through the mesothelioma information portal. Here, an individual can be referred to an experienced mesothelioma attorney who will have important information on the legal implications of exposure to asbestos.

In addition to mesothelioma, LegalView also provides information portals on topics such as traumatic brain injury (TBI), Singulair side effects and the Baxter Heparin recall. TBIs adversely affect millions of Americans each year and thousands of these cases go unreported even though the effects may be severe. TBI side effects range from memory loss to poor motor and social skills to paralysis. Individuals who have been injured in a traumatic brain injury should use the LegalView TBI information portal to locate an attorney as well as to learn about the latest TBI treatments.

On the Singulair practice area, readers will learn of the latest U.S. Food and Drug Administration (FDA) investigation into the allergy symptom drug. The investigation stems from patient reports that there may be some Singulair side effects that are causing an increased risk of suicidal thoughts among patients.

Learn the latest updates on the FDA's investigation into the Baxter Heparin recall, which was spurred by a rash of allergic reactions among patients who had previously received the drug during surgical procedures. Most recently, the FDA discovered that a Chinese manufacturing plant was responsible for a tainted batch of Baxter Heparin. The drug is a blood thinner used to decrease the risk of deadly blood clots during surgical procedures such as heart surgery.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at
www.LegalView.com.

Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website:
http://mesothelioma.legalview.com


Monday, May 05, 2008

 

Deep Brain Stimulation Study Offers Hope for Severe Depression Patients

Results of Brodmann Area 25 Deep Brain Stimulation Pilot Study Offer Hope for Patients with Severe Depression

Study findings presented today at American Psychiatric Association Annual Meeting


ST. PAUL, Minn.-- May 05, 2008 --St. Jude Medical, Inc. (NYSE:STJ) today announced pilot study results from the first multi-center study investigating deep brain stimulation (DBS) of Brodmann Area 25 for major depressive disorder.

Results of the study, which were presented today at the American Psychiatric Association (APA) meeting in Washington, D.C., found that 6 months after the procedure, 56 percent of the patients experienced at least a 40 percent decrease in depressive symptoms. Patient's symptoms were measured using a standardized test called the Hamilton Rating Scale for Depression.

Results were presented by Sidney Kennedy, M.D., psychiatrist-in-chief with the University Health Network in Toronto. "Severe depression destroys a person's ability to be productive and have a normal quality of life," said Dr. Kennedy. "The results from this study are very promising, and we are hopeful that our research will lead to a therapy that can help these patients."

Prior to beginning the study, all patients were classified as having severe depression after multiple treatments - such as medications, psychotherapy and electroconvulsive therapy - had failed to provide sustained relief from depression. Each study patient had tried a minimum of 12 depression medications over his or her lifetime.

DBS was targeted at an area of the brain known as Brodmann Area 25, which appears to become overactive when people are profoundly sad and depressed. Conducted at three leading Canadian academic medical centers, the study expands and supports the groundbreaking research of Helen Mayberg, M.D., and Andres Lozano, M.D., which was published in Neuron in March 2005.

On average, the 20 study participants had suffered from depression for more than 20 years; they were disabled and unable to work at the time of enrollment. The study also found that:

    * At their most recent psychiatric evaluation, 78 percent of the patients experienced at least a 40 percent decrease in depressive symptoms.
    * Three of the study patients are considered to be in remission.
    * Eight patients have re-engaged in life activities such as work, school, relationships and travel.

In the study, DBS was delivered through the St. Jude Medical Libra® Deep Brain Stimulation System, which delivers mild electrical current from a device implanted near the collarbone; the device is connected to small electrical leads placed at specific targets in the brain.

"These results are important as they help establish the body of evidence that will continue to move depression research forward," said Chris Chavez, president of the St. Jude Medical ANS Division. "We are committed to leading the development of products that can make life better for patients suffering from this debilitating condition."

Based on the results of this research, St. Jude Medical announced the BROADENT (BROdmann Area 25 DEep brain Neuromodulation) study in February 2008, to further investigate the use of DBS for major depressive disorder. A controlled, multi-center, blinded clinical study, BROADEN is being conducted in the U.S. under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA).

St. Jude Medical owns the intellectual property rights and has various patents issued and pending for the use of neurostimulation at Brodmann Area 25. For more information about this clinical trial, call toll-free 866-787-4332 or visit www.BROADENstudy.com.

According to the National Advisory Mental Health Council, of the 21 million adult Americans who suffer from depression, approximately 4 million live with severe depression that does not respond to medications, psychotherapy and, in certain cases, electroconvulsive therapy.

About St. Jude Medical

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide. For more information, please visit www.sjm.com.

About the ANS Division of St. Jude Medical

The ANS Division (Advanced Neuromodulation Systems) became a part of St. Jude Medical in 2005. The ANS Division is an innovative technology leader dedicated to the design, development, manufacturing and marketing of implantable neuromodulation systems to improve the quality of life for people suffering from disabling chronic pain and other nervous system disorders (www.ans-medical.com).

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's Annual Report on Form 10-K filed on February 27, 2008 (see Item 1A on pages 13-20, and page 20 of Exhibit 13 to the Company's Form 10-K). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contacts

St. Jude Medical, Inc.
Investor Relations:
Angela Craig, 651-481-7789
or
Media Relations:
Kathleen Janasz, 651-415-7042
Mobile: 612-743-8995
or
Denise Landry, 972-309-8085


Thursday, May 01, 2008

 

Infectious Disease Research Institute Collaborates With 3M On Vaccine Adjuvants

3M Collaborates with Infectious Disease Research Institute on Vaccine Adjuvants

ST. PAUL, Minn.-- May 01, 2008 --3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with the Infectious Disease Research Institute (IDRI) in support of vaccine research for humanitarian efforts in developing countries. Under the agreement, 3M will donate its patented toll-like receptor (TLR) immune response modifier compounds.

3M's patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by IDRI to research new vaccines. Vaccine adjuvants are known to help boost the effectiveness of a vaccine.

"IDRI's vaccine platform has the potential to prevent and treat a number of important diseases in the developing world. By providing our vaccine adjuvant compounds to their vaccines, we are providing a cost-effective way for IDRI to conduct vaccine research," said Dr. Mark Tomai, PhD, Vaccine Business Development, 3M Drug Delivery Systems. "This will help them and us learn more about the potential effectiveness of our vaccine adjuvants. We anticipate this collaboration with IDRI to be the first in many deals around our TLR vaccine adjuvant portfolio."

3M's TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

"IDRI's access to a 3M compound provides us with a very important tool for our efforts to develop adjuvants to be used in vaccines for diseases of global impact," says Steve Reed, IDRI's Founder and Head of Research. "We are very pleased that 3M has demonstrated this confidence in our organization-and are confident that IDRI's access to the 3M technology will improve our vaccine research and development."

"Our toll-like receptor agonist platform is a major part of our vaccine offering that also includes our Microstructured Transdermal System(a) for needle-free delivery of vaccines. We are at the start of a positive relationship that pairs our unique technology with a critical global need. We look forward to working with IDRI on its vaccine research," said Dr. Steven Wick, Technical Director, 3M Drug Delivery Systems.

About 3M Drug Delivery Systems Immune Response Modifiers

3M Drug Delivery Systems has a portfolio of patent protected toll-like receptor TLR7 and TLR8 agonists that have shown promise as vaccine adjuvants. There are a variety of assets in the portfolio that can be used topically, admixed or in conjugatable form. The lead candidate, resiquimod (TLR7/8 agonist) has shown promising results in a number of animal models and has an extensive toxicology and clinical data package to support further development as a vaccine adjuvant. In addition, 3M offers other TLR7 and TLR8 agonists, some of which can be attached to various proteins that enhance vaccine efficacy in a number of models. As small molecules, 3M's TLR7 and TLR8 agonists offer unique advantages over other TLR agonists with regards to delivery and manufacturing. 3M is actively seeking partners to license these assets on a non-exclusive basis. For more information, or to contact Dr. Tomai, go to www.3m.com/dds.

In addition, 3M Drug Delivery Systems has a variety of immune response modifier compounds that may be useful in oncology and dermatology.

About 3M

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries.

About IDRI

IDRI is a non-profit organization committed to developing technologies to treat "neglected" diseases that place a significant burden on those living in the developing world. IDRI achieves its mission by working closely with industry, universities, and hospitals in developed and developing countries, government and private funding agencies, the Bill and Melinda Gates Foundation as well as the World Health Organization. For more information, go to www.idri.org.

(a)3M Microstructured Transdermal System (MTS) is a state-of-the-art solid microneedle system for transcutaneous or intra-dermal drug delivery. MTS bypasses the barrier properties of the stratum corneum and provides a means to deliver a wide variety of molecules that ordinarily would not penetrate the skin, including vaccines. MTS enhances the efficacy of vaccines by targeting the antigen presenting cells within the skin, thereby improving delivery efficiency and reducing dose requirements. MTS is a painless, easy-to-use system with the potential to greatly improve the delivery of vaccines.
Contacts

3M
Stephanie Sanderson, 651-733-8588
sjsanderson@mmm.com


Some other health and medical resources to consider include ADA diabetes, laser eye clinics, psoriatic arthritis, and fibromyalgia diagnosis.


Health blogs Health Blogs